Aclaris Therapeutics
ACRS
98 hedge funds and large institutions have $217M invested in Aclaris Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 15 closing their positions.
271% more capital invested
Capital invested by funds: $58.5M → $217M (+$158M)
128% more call options, than puts
Call options by funds: $850K | Put options by funds: $372K
127% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 15
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
51.14% more ownership
Funds ownership: 71.35% → 122.49% (+51%)
21% more funds holding
Funds holding: 81 → 98 (+17)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$24M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$22.1M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.6M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$8.59M |
| 5 |
Janus Henderson Group
London,
|
+$6.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.47M |
| 2 |
Millennium Management
New York
|
-$2.6M |
| 3 |
TC
Trium Capital
London,
United Kingdom
|
-$2.2M |
| 4 |
Renaissance Technologies
New York
|
-$1.29M |
| 5 |
BlackRock
New York
|
-$1.13M |
ACRS Hedge Fund Activity: Q4 2024 in Review
98 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2024, worth a combined $217M — up 271% from $58.5M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ACRS positions and 15 closed out — a net gain of 19 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $24M. The largest seller was Stonepine Capital Management, cutting an estimated $4.47M.
- 98 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2024, up from 81 in Q3 2024.
- Funds reported $217M of Aclaris Therapeutics stock for Q4 2024, up 271% quarter-over-quarter.
- 34 funds opened new Aclaris Therapeutics positions in Q4 2024 and 15 closed out, a net change of +19 holders.
- The largest Aclaris Therapeutics buyer in Q4 2024 was Adage Capital Partners, an estimated $24M added.
- The largest Aclaris Therapeutics seller in Q4 2024 was Stonepine Capital Management, an estimated $4.47M sold.
Based on aggregated 13F filings for Q4 2024.